$18.87
10.09%
NYSE, Aug 22, 10:13 pm CET
ISIN
US80880W1062
Symbol
SCLX

Scilex Stock price

$18.87
+10.03 113.46% 1M
+7.81 70.56% 6M
+3.95 26.44% YTD
-23.83 55.81% 1Y
-343.03 94.79% 3Y
-325.88 94.53% 5Y
-325.88 94.53% 10Y
-325.88 94.53% 20Y
NYSE, Closing price Fri, Aug 22 2025
+1.73 10.09%
ISIN
US80880W1062
Symbol
SCLX
Industry

Key metrics

Basic
Market capitalization
$131.3m
Enterprise Value
$252.8m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.8 | 2.3
EV/Sales
5.4 | 4.4
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-170.7%
Return on Equity
96.6%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | $58.0m
EBITDA
- | -
EBIT
- | $-73.4m
Net Income
- | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | 24.2%
EBITDA
- | -
EBIT
- | 30.4%
Net Income
- | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
10.8%
Employees
31
Rev per Employee
$1.5m
Show more

Is Scilex a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,020 stocks worldwide.

Scilex Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Scilex forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Scilex forecast:

Buy
75%
Hold
25%

Financial data from Scilex

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '23
+/-
%
47 47
292% 292%
100%
- Direct Costs 16 16
248% 248%
34%
31 31
319% 319%
66%
- Selling and Administrative Expenses 120 120
409% 409%
256%
- Research and Development Expense 13 13
390% 390%
27%
-101 -101
380% 380%
-217%
- Depreciation and Amortization 4.11 4.11
299% 299%
9%
EBIT (Operating Income) EBIT -105 -105
376% 376%
-226%
Net Profit -167 -167
867% 867%
-357%

In millions USD.

Don't miss a Thing! We will send you all news about Scilex directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Head office United States
CEO Jaisim Shah
Employees 31
Founded 2020
Website www.scilexholding.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today